Pairidex
Latest round
- Seed
Last raised
- Feb 2026
Total raised
- $4.9M
Investors
- 2
About Pairidex
, founded by Andrew Young (Founder & Chief Scientific Officer), provides personalized molecular diagnostic testing and measurable residual disease (MRD) monitoring solutions for blood cancers through its FusionMRD™ platform for the healthcare and life sciences industry. The company generates revenue by providing FusionMRD™ blood cancer testing services and personalized molecular diagnostic solutions for disease monitoring.
Who invested in Pairidex
2 investors across 1 round
See all investors in Pairidex
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Feb 23, 2026
Amount
$4.9M
Investors
Questions about Pairidex
Who invested in Pairidex?
Pairidex has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Pairidex raised?
Pairidex has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Pairidex last raise money?
Pairidex's most recent round on record is a Seed, in Feb 2026.
What does Pairidex do?
, founded by Andrew Young (Founder & Chief Scientific Officer), provides personalized molecular diagnostic testing and measurable residual disease (MRD) monitoring solutions for blood cancers through its FusionMRD™ platform for the healthcare and life sciences industry.
Where is Pairidex headquartered?
Pairidex is headquartered in St. Louis, US.
Which VCs invest in companies like Pairidex?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Pairidex's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Pairidex? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.